https://charts.traderzeitung.de/phases/US02043Q1076
string(1447) "{"isin":"US02043Q1076","name":"Alnylam Pharmaceuticals Inc","stock_id_xnas":7873158,"stock_id_xnys":null,"generated_at":"2026-07-08 15:34:00","days":[{"date":"2026-07-06","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":316.8,"close_at":"2026-07-06 13:28:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":310.08,"close_at":"2026-07-06 16:09:00","complete":true,"perf_pct":-2.1212},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-07-07","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":315,"close_at":"2026-07-07 10:14:00","complete":true,"perf_pct":1.5867},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":321.66,"close_at":"2026-07-07 21:59:00","complete":true,"perf_pct":2.1143},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-07-08","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":317.78,"close_at":"2026-07-08 15:33:00","complete":false,"perf_pct":-1.2062},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Alnylam Pharmaceuticals Aktie News & Nachrichten
Das Biotechunternehmen hat sich auf Medikamente auf Basis der RNA-Interferenz (RNAi) spezialisiert,...
